Lidanserin is a drug which acts as a combined 5-HT2A and α1-adrenergic receptor antagonist. In conscious spontaneously hypertensive rats intravenous injection of lidanserin caused dose-dependent blood pressure reductions. Lidanserin antagonises the excitatory effect of synaptically released 5-HT on central sympathoexcitatory neurons. Lidanserin is a potential antihypertensive compound which combines vasodilatatory effects due to selective alpha 1-receptor antagonistic action and platelet antiaggregatory, antivasospastic, and vasoprotective properties due to selective 5-HT2-receptor blockade.

Pirandamine is the potential antidepressant drug. It is a relatively selective inhibitor of the serotonin uptake mechanism and does not exhibit appreciable norepinephrine uptake blocking activity in contrast to the tricyclic antidepressant drugs imipramine and amitriptyline. Pirandamine is equivalent to amitriptyline and greater than imipramine in potency as a serotonin uptake blocker and a potentiator of central serotonin pharmacological actions, and in contrast, does not exhibit appreciable central anticholinergic effects. Pirandamine potentiated the behavioral effects of 5-hydroxytryptophan in mice. Pirandamine, in contrast to desimipramine and imipramine, did not prevent reserpine-induced hypothermia. The (-)-enantiomer of pirandamine retained the activity of the racemate; the (+I-enantiomer was much less effective.

Ozolinone, an active metabolite of diuretic etozoline was studied also as a loop diuretic. Experiments on dogs have shown that ozolinone, induced stereoselective and prostaglandin-dependent renin secretion, which was involved in the regulation of intra-renal hemodynamics. Information about the current use of this drug is not available.

Dioxaphetyl butyrate is a synthetic narcotic analgesic and spasmolytic agent that has no accepted medicinal value in the United States. This opioid drug under international control according to the UN Single Convention 1961 and its amendments, Schedule I.

Omtriptolide (previously known as PG490-88 or F60008), an immunosuppressant that has been shown to be the safe and potent antitumor agent and it has been approved entry into Phase I clinical trial for the treatment of prostate cancer in the USA. In addition, the drug is participating in phase I clinical trial for the treatment of myeloid leukemia. Experiments on animals have shown omtriptolide was highly effective in the prevention of murine graft-versus-host disease (GVHD). The immunosuppressive effect of the drug was mediated by inhibition of alloreactive T cell expansion through interleukin-2 production. However, this study was discontinued. Recently published article has shown omtriptolide possesses the potential as a prophylactic agent to prevent ischemia/reperfusion (I/R)-induced lung injury.